Strongbridge Biopharma plc - Ordinary Shares (SBBP): Price and Financial Metrics


Strongbridge Biopharma plc - Ordinary Shares (SBBP): $3.14

-0.07 (-2.18%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

SBBP Stock Summary

  • For SBBP, its debt to operating expenses ratio is greater than that reported by only 11.59% of US equities we're observing.
  • Over the past twelve months, SBBP has reported earnings growth of -184.61%, putting it ahead of only 10.61% of US stocks in our set.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for SBBP comes in at -17.23% -- higher than that of just 13.68% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Strongbridge Biopharma plc are ALKS, MRCY, EBS, HLIT, and AGE.
  • SBBP's SEC filings can be seen here. And to visit Strongbridge Biopharma plc's official web site, go to www.strongbridgebio.com.

SBBP Stock Price Chart Interactive Chart >

Price chart for SBBP

SBBP Price/Volume Stats

Current price $3.14 52-week high $4.63
Prev. close $3.21 52-week low $1.50
Day low $3.08 Volume 626,118
Day high $3.35 Avg. volume 846,840
50-day MA $2.96 Dividend yield N/A
200-day MA $3.04 Market Cap 211.15M

Strongbridge Biopharma plc - Ordinary Shares (SBBP) Company Bio


Strongbridge Biopharma PLC is focused on the development, in-licensing, acquisition and eventual commercialization of complementary product candidates across multiple franchises that target rare diseases. The company was founded in 1996 and is based in Trevose, Pennsylvania.


SBBP Latest News Stream


Event/Time News Detail
Loading, please wait...

SBBP Latest Social Stream


Loading social stream, please wait...

View Full SBBP Social Stream

Latest SBBP News From Around the Web

Below are the latest news stories about Strongbridge Biopharma plc that investors may wish to consider to help them evaluate SBBP as an investment opportunity.

Thinking about buying stock in G1 Therapeutics, Strongbridge Biopharma, Soligenix, Pieris Pharmaceuticals, or Diffusion Pharmaceuticals?

NEW YORK, Feb. 16, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GTHX, SBBP, SNGX, PIRS, and DFFN. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link….

PR Newswire | February 16, 2021

Strongbridge Biopharma plc Announces New Employment Inducement Awards

DUBLIN, Ireland and TREVOSE, Pa., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that it has approved inducement equity awards to ten individuals who have recently become, or are expected to become, employees of the Company. The inducement awards are being made in the form of non-qualified stock options to purchase an aggregate of 154,800 ordinary shares of the Company, and are being made as a material inducement to these individuals to enter into employment with the Company pursuant to NASDAQ Listing Rule 5635(c)(4). The exercise price for each of the options is equal to the closi...

Yahoo | February 3, 2021

Strongbridge Biopharma plc Announces Preliminary Fourth Quarter and Full-Year 2020 Financial Results and Provides Corporate Update

~ Expects to Report KEVEYIS® (dichlorphenamide) Fourth Quarter 2020 Revenue of Approximately $8.2 Million and Full-Year 2020 Revenue of Approximately $30.7 Million, a 41.5 Percent Increase over 2019 Revenue of $ $21.7 Million ~~ Targets Full-Year 2021 KEVEYIS® (dichlorphenamide) Revenue Guidance of Approximately $34 Million to $36 Million ~~ Company on Track to Submit New Drug Application (NDA) for RECORLEV® (levoketoconazole) to the FDA in the First Quarter of 2021 ~~ Company Exercised its Option to Draw-Down an Additional $10 Million Under its Existing Debt Facility in the Fourth Quarter of 2020; Approximately $87.5 Million in Cash on Hand is Expected to Fund Operations Into and Potentially Beyond the First Quarter of 2023 ~DUBLIN, Ireland and TREVOSE, Pa., Jan. 06, 2021 (GLOBE NEWSWI...

Yahoo | January 6, 2021

Is Strongbridge Biopharma (NASDAQ:SBBP) Using Debt Sensibly?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...

Yahoo | January 4, 2021

Is SBBP A Good Stock To Buy Now?

Many prominent investors, including Warren Buffett, David Tepper and Stan Druckenmiller, have been cautious regarding the current bull market and missed out as the stock market reached another high in recent weeks. On the other hand, technology hedge funds weren’t timid and registered double digit market beating gains. Financials, energy and industrial stocks aren’t doing […]

Yahoo | December 14, 2020

Read More 'SBBP' Stories Here

SBBP Price Returns

1-mo 16.30%
3-mo 13.77%
6-mo -13.74%
1-year 16.30%
3-year -56.99%
5-year -20.30%
YTD 29.22%
2020 16.27%
2019 -53.35%
2018 -38.21%
2017 202.08%
2016 -68.42%

Continue Researching SBBP

Here are a few links from around the web to help you further your research on Strongbridge Biopharma plc's stock as an investment opportunity:

Strongbridge Biopharma plc (SBBP) Stock Price | Nasdaq
Strongbridge Biopharma plc (SBBP) Stock Quote, History and News - Yahoo Finance
Strongbridge Biopharma plc (SBBP) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.7724 seconds.